TY - JOUR
T1 - Altered Gut Microbiota in a Fragile X Syndrome Mouse Model
AU - Altimiras, Francisco
AU - Garcia, José Antonio
AU - Palacios-García, Ismael
AU - Hurley, Michael J.
AU - Deacon, Robert
AU - González, Bernardo
AU - Cogram, Patricia
N1 - Funding Information:
We would like to thank David Nelson and FRAXA for providing the mice used in this study. We would also like to thank the Institute of Ecology and Biodiversity (IEB) and all the Neurogenetics laboratory, specially Daniel Benitez and Jorge Ruiz, our veterinary doctor. We are very grateful to the members of the Center for Bioengineering and the members of the Complex Systems Ph. D. Program at Universidad Adolfo Ibáñez. We would further like to thank Ignacio Ramos and Eduardo Castro-Nallar from the Center for Bioinformatics and Integrative Biology at Universidad Andrés Bello. Funding. This work was supported by the Fragile X Research Foundation, United States. FA was supported by the INF-PUCV Scholarship. JG was supported by the grant CONICYT/FONDECYT/INICIACION/11180056. IP-G was supported by the grant FONDECYT/POSTDOCTORAL/3190491. BG was supported by the grant ANID PIA/BASAL FB0002. PC was supported by the grant ANID/FONDECYT/REGULAR/1200928.
Funding Information:
This work was supported by the Fragile X Research Foundation, United States. FA was supported by the INF-PUCV Scholarship. JG was supported by the grant CONICYT/ FONDECYT/INICIACION/11180056. IP-G was supported
Publisher Copyright:
© Copyright © 2021 Altimiras, Garcia, Palacios-García, Hurley, Deacon, González and Cogram.
PY - 2021/5/26
Y1 - 2021/5/26
N2 - The human gut microbiome is the ecosystem of microorganisms that live in the human digestive system. Several studies have related gut microbiome variants to metabolic, immune and nervous system disorders. Fragile X syndrome (FXS) is a neurodevelopmental disorder considered the most common cause of inherited intellectual disability and the leading monogenetic cause of autism. The role of the gut microbiome in FXS remains largely unexplored. Here, we report the results of a gut microbiome analysis using a FXS mouse model and 16S ribosomal RNA gene sequencing. We identified alterations in the fmr1 KO2 gut microbiome associated with different bacterial species, including those in the genera Akkermansia, Sutterella, Allobaculum, Bifidobacterium, Odoribacter, Turicibacter, Flexispira, Bacteroides, and Oscillospira. Several gut bacterial metabolic pathways were significantly altered in fmr1 KO2 mice, including menaquinone degradation, catechol degradation, vitamin B6 biosynthesis, fatty acid biosynthesis, and nucleotide metabolism. Several of these metabolic pathways, including catechol degradation, nucleotide metabolism and fatty acid biosynthesis, were previously reported to be altered in children and adults with autism. The present study reports a potential association of the gut microbiome with FXS, thereby opening new possibilities for exploring reliable treatments and non-invasive biomarkers.
AB - The human gut microbiome is the ecosystem of microorganisms that live in the human digestive system. Several studies have related gut microbiome variants to metabolic, immune and nervous system disorders. Fragile X syndrome (FXS) is a neurodevelopmental disorder considered the most common cause of inherited intellectual disability and the leading monogenetic cause of autism. The role of the gut microbiome in FXS remains largely unexplored. Here, we report the results of a gut microbiome analysis using a FXS mouse model and 16S ribosomal RNA gene sequencing. We identified alterations in the fmr1 KO2 gut microbiome associated with different bacterial species, including those in the genera Akkermansia, Sutterella, Allobaculum, Bifidobacterium, Odoribacter, Turicibacter, Flexispira, Bacteroides, and Oscillospira. Several gut bacterial metabolic pathways were significantly altered in fmr1 KO2 mice, including menaquinone degradation, catechol degradation, vitamin B6 biosynthesis, fatty acid biosynthesis, and nucleotide metabolism. Several of these metabolic pathways, including catechol degradation, nucleotide metabolism and fatty acid biosynthesis, were previously reported to be altered in children and adults with autism. The present study reports a potential association of the gut microbiome with FXS, thereby opening new possibilities for exploring reliable treatments and non-invasive biomarkers.
KW - autism spectrum disorders
KW - biomarkers
KW - drug development
KW - drug targets
KW - fragile X syndrome
KW - gut microbiota
KW - mouse models
KW - neuroinflammation
UR - http://www.scopus.com/inward/record.url?scp=85107549507&partnerID=8YFLogxK
U2 - 10.3389/fnins.2021.653120
DO - 10.3389/fnins.2021.653120
M3 - Article
AN - SCOPUS:85107549507
SN - 1662-4548
VL - 15
JO - Frontiers in Neuroscience
JF - Frontiers in Neuroscience
M1 - 653120
ER -